SCHEMBL1762286

SCHEMBL1762286

CCc1ccccc1-c1cccc(-n2cnc3cc(C(N)=NO)ccc32)c1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 4/20 0.49
HPGD P15428 7/20 0.48
ALDH1A1 P00352 2/20 0.48
LMNA P02545 1/20 0.48
GABRA1 P14867 2/20 0.47
GABRG2 P18507 2/20 0.47
GABRB3 P28472 2/20 0.47
GABRA5 P31644 2/20 0.47
GABRA3 P34903 2/20 0.47
GABRA2 P47869 1/20 0.47
TP53 P04637 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 1/20 0.41
GLA P06280 1/20 0.41
RAB9A P51151 1/20 0.41
GRM5 P41594 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1762116 0.87 FGFR1 (0.49) FGFR1HPGDALDH1A1GABRA1GABRG2
SCHEMBL1761928 0.87 GABRA1 (0.49) FGFR1HPGDGABRA1GABRG2GABRB3
SCHEMBL1762237 0.85 FGFR1 (0.49) FGFR1HPGDALDH1A1GABRA1GABRG2
SCHEMBL1761682 0.84 HPGD (0.45) FGFR1HPGDALDH1A1GABRA1GABRG2
SCHEMBL1761892 0.83 FGFR1 (0.45) FGFR1HPGDALDH1A1GABRA1GABRG2
SCHEMBL1762285 0.82 HPGD (0.48) FGFR1HPGDALDH1A1LMNAGABRA1
SCHEMBL1761647 0.82 FGFR1 (0.45) FGFR1HPGDALDH1A1GABRA1GABRG2
SCHEMBL1761948 0.81 GABRA1 (0.47) FGFR1HPGDALDH1A1GABRA1GABRG2
SCHEMBL1762260 0.81 GABRA1 (0.46) FGFR1HPGDALDH1A1LMNAGABRA1
SCHEMBL1761961 0.81 GABRA1 (0.45) FGFR1HPGDALDH1A1GABRA1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118259-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX SANIONA A/S (DK) 2011-05-19 US claimed
EP-2319837-A1 Benzimidazole derivatives and their use for modulating the GABAa receptor complex NeuroSearch AS (DK) 2011-05-11 EP claimed
US-20090036476-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX SANIONA A/S (DK) 2009-02-05 US claimed
US-8288418-B2 Benzimidazole derivatives and their use for modulating the GABAA receptor complex NEUROSEARCH A/S (DK) 2012-10-16 US disclosed
US-20110118259-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX SANIONA A/S (DK) 2011-05-19 US disclosed
EP-2319837-A1 Benzimidazole derivatives and their use for modulating the GABAa receptor complex NeuroSearch AS (DK) 2011-05-11 EP disclosed
US-7902230-B2 Benzimidazole derivatives and their use for modulating the GABAA receptor complex NEUROSEARCH A/S (DK) 2011-03-08 US disclosed
US-20090036476-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX SANIONA A/S (DK) 2009-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036476-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX GABRB2, GABRB1, GABRB3 FGFR1 3907/4885HPGD 1966/4885ALDH1A1 491/4885
US-20110118259-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX GABRB2, GABRB1, GABRB3 FGFR1 3907/4885HPGD 1966/4885ALDH1A1 491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.